Mickael Naassila

Prof. Mickael Naassila

INSERM - Institut National de la Santé et de la Recherche Médicale
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2004 in Neuropsychopharmacology
Verified
Journal Article
Closed access
HHHakim Houchi
Hakim Houchi
DBDaniela Babovic
Daniela Babovic
OPOlivier Pierrefiche
Olivier Pierrefiche
CLCatherine Ledent
Catherine Ledent
MDMartine Daoust
Martine Daoust
Mickael NaassilaMickael Naassila
Mickael Naassila

1 April 2013 in Neuropharmacology
Verified
Journal Article
Closed access
SAStéphanie Alaux-Cantin
Stéphanie Alaux-Cantin
VWVincent Warnault
Vincent Warnault
RLRémi Legastelois
Rémi Legastelois
BBBéatrice Botia
Béatrice Botia
OPOlivier Pierrefiche
Olivier Pierrefiche
Mickael NaassilaMickael Naassila
Mickael Naassila

1 February 2004 in Neuropharmacology
Verified
Journal Article
Closed access
Mickael NaassilaMickael Naassila
Mickael Naassila
OPOlivier Pierrefiche
Olivier Pierrefiche
CLCatherine Ledent
Catherine Ledent
MDMartine Daoust
Martine Daoust

1 February 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
FLF. Lorget
F. Lorget
SKS. Kamel
S. Kamel
RMR. Mentaverri
R. Mentaverri
AWA. Wattel
A. Wattel
Mickael NaassilaMickael Naassila
Mickael Naassila
MBM. Brazier
M. Brazier

20 May 2009 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
CVCatherine Vilpoux
Catherine Vilpoux
VWVincent Warnault
Vincent Warnault
OPOlivier Pierrefiche
Olivier Pierrefiche
MDMartine Daoust
Martine Daoust
Mickael NaassilaMickael Naassila
Mickael Naassila

1 December 2002 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
Mickael NaassilaMickael Naassila
Mickael Naassila
CLCatherine Ledent
Catherine Ledent
MDMartine Daoust
Martine Daoust
We have shown previously that the severity of handling-induced convulsions during ethanol withdrawal was reduced in A2Areceptor knock-out (A2AR−/−) mice. In the present report, we further characterize the role of adenosine A2A receptors in ethanol consumption and neurobiological responses to this drug of abuse. Male A2AR−/− mice showed increased consumption of solutions containing 6 and 20% (v/v) ethanol compared with wild-type (A2AR+/+) control mice; female A2AR−/− mice showed increased consumption of solutions containing 6 and 10% ethanol. This slightly higher ethanol consumption was also related to increased ethanol preference. In contrast, A2AR−/− mice showed normal consumption of solutions containing either sucrose or quinine. Relative to A2AR+/+ mice, A2AR−/− mice were found to be less sensitive to the sedative effect of 3.0 gm/kg ethanol, as measured by more rapid recovery from ethanol-induced loss of righting reflex, and to the hypothermic effects of 1.5, 3.0, and 4.0 gm/kg ethanol, although plasma ethanol levels did not differ significantly between the two genotypes. The selective adenosine A2A receptor antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol) (10–30 mg/kg) significantly attenuated ethanol-induced (4.0 gm/kg) hypothermia in CD1 mice. To assess whether ethanol administration would induce differential tolerance in A2AR−/− and wild-type mice, we administered ethanol (3.0 gm/kg) over 4 consecutive days and found no difference in the development of tolerance; however, female A2AR−/− mice showed a lower tolerance-acquisition rate. These data suggest that activating the A2A receptors may play a role in suppressing alcohol-drinking behavior and is associated with the sensitivity to the intoxicating effects of acute ethanol administration.